Project Grant 2537833
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $511,798 was awarded to Kilele Health Inc. on June 15, 2022 to develop continuous diagnostic monitoring platforms beyond glucose sensing. Unlike existing enzymatic glucose sensors, the company will utilize electrochemical aptamer sensors that can rapidly measure other molecules in the body with high specificity and sensitivity. The aim is to address limitations that have...
- The National Science Foundation awarded $304,950 to Senphonix, Inc. on October 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop injection-molded biosymbiotic devices for long-term, multimodal physiological monitoring as a Small Business Technology Transfer (STTR) Phase I project. The work centers on designing and demonstrating a lightweight mesh wearable sleeve with embedded microsensors, coupled with wireless charging electronics, remote radio...
- The National Science Foundation awarded Deleon Technologies, Inc. $305,000 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a low-cost, single-use microfluidic chip that performs capillary electrophoresis with laser-induced fluorescence detection for daily personalized metabolomics monitoring. The project will validate the feasibility of manufacturing a disposable microchip capable of automated chemical analysis of urine in minutes at home,...
- This $500,000 Project Grant award from the National Science Foundation (NSF) Computer and Information Science and Engineering (CISE) program supports the development of a novel materials-based sensing system for detecting a variety of analytes or physiological states in biological fluids. The multidisciplinary team from Lehigh University, led by researchers in chemistry, materials science, bioengineering, and computer science, aims to create an initially "analyte-agnostic" nanosensor...
- The National Science Foundation awarded AMG Detection, Inc. $305,000 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a wearable carbon nanotube sensor array for seizure prediction. The project aims to create the first scalable, non-invasive wearable device capable of predicting epileptic seizures 10–45 minutes before onset by detecting a validated panel of nine pre-seizure volatile organic compounds emitted from the skin. Current seizure...
- The National Science Foundation awarded Integrated Medical Sensors Inc. a $256,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel multi-analyte microsensor platform for continuous wireless monitoring applications. The grant aims to create a unique monolithic semiconductor platform capable of wirelessly monitoring multiple biochemical and physiological markers simultaneously in a sub-cubic millimeter footprint. This miniature,...
- The National Science Foundation awarded Raylife Inc. $304,898 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop novel optoelectronics technology for non-invasive, continuous blood glucose monitoring. This SBIR Phase I project investigates a broadband optoelectronic platform that uses volumetric spatiotemporal spectroscopy across the visible, near-infrared, and shortwave infrared spectrum (500–2,500 nanometers) to measure glucose without...
- The National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded a $450,000 Project Grant to the Texas A&M Engineering Experiment Station (Tees) to develop an injectable, grain-of-rice size glucose biosensor for continuous blood sugar monitoring. The key products or services to be provided under this 3-year grant include: Developing an injectable glucose biosensor comprised of a self-cleaning membrane and a near-infrared fluorescence...
- The National Science Foundation (NSF) awarded a $305,000 STTR Phase I project grant to Sensvita Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a non-invasive radio frequency sensing technology for home-based monitoring of heart and lung function. The proposed system uses advanced sensing methods to measure critical physiological parameters without the need for skin contact or maintenance, improving the convenience, scalability,...
- The National Institute of General Medical Sciences awarded Cambridge Medical Technologies LLC $1,010,698 on September 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a noninvasive biosensor for measurement and serial monitoring of lactate levels using interstitial fluid extraction. Cambridge Medical Technologies will improve device hardware and software for clinical use and perform in vitro experiments to optimize electrochemical measurement accuracy...
The National Science Foundation awarded Levosens, Inc., $305,000 on August 15, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an electrochemical biosensing platform integrating machine learning and multimodal electrochemical sensing for real-time biomarker detection. The recipient will address limitations of current biosensors by combining multiple electrochemical sensing modalities to improve signal quality, sensitivity, and analyte specificity while capturing biomarker dynamics over broad physiological ranges. The project targets real-time monitoring of analytes including levodopa and lactate, which require detection within narrow therapeutic windows or rapid fluctuation tracking during critical illness. Phase I deliverables include sensor signal acquisition, machine learning model development, and in vitro and ex vivo validation using human plasma. Key technical innovations involve engineered direct electron transfer enzymes for substrate-specific responses and machine learning models trained to interpret complex signal features while minimizing noise. The work will establish a modular framework applicable to additional analytes and represents early integration of machine learning with multimodal electrochemical sensing. Work is performed in Chapel Hill, North Carolina, with a period of performance from August 15, 2026, through July 31, 2027. The Small Business Technology Transfer (STTR) Phase I award supports interdisciplinary innovation and industry-academic collaboration in digital health technology.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $305.0k | 8/11/26 |